Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11135325 | 0.83 | OPRM1 (0.41) | ALOX5OPRM1OPRD1OPRK1PTPN1 | |
| SCHEMBL1688846 | 0.81 | CRHR1 (0.40) | OPRK1CRHR1CYP3A4 | |
| SCHEMBL9861522 | 0.78 | ALDH1A1 (0.42) | ALOX5OPRM1OPRD1OPRK1PTPN1 | |
| SCHEMBL11129148 | 0.77 | CYP3A4 (0.38) | ALOX5OPRM1OPRD1OPRK1CRHR1 | |
| SCHEMBL7902140 | 0.74 | ALDH1A1 (0.44) | ESR2ESR1CYP3A4TSHRRECQL | |
| SCHEMBL21426606 | 0.74 | CNR1 (0.38) | OPRK1CRHR1CYP3A4 | |
| SCHEMBL10970326 | 0.73 | ESR1 (0.41) | ALOX5OPRM1OPRD1OPRK1PTPN1 | |
| SCHEMBL544101 | 0.73 | C5AR1 (0.44) | ALOX5CRHR1PTPN1CYP3A4TSHR | |
| SCHEMBL1018958 | 0.72 | ESR1 (0.45) | ALOX5OPRM1OPRD1OPRK1PTPN1 | |
| SCHEMBL3050943 | 0.72 | ALDH1A1 (0.50) | CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933129-B2 | Compounds and methods for modulating activity of calcium release channels | STATE OF OREGON BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120101085-A1 | Compounds And Methods For Modulating Activity Of Calcium Release Channels | State of Oregon by and through the State Board of Higher Education on behalf of Portland State Univ. (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2418950-A1 | COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS | State Of Oregon By&Through The State Board Of Higher Education On Behalf Of Portland State Unv. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120382-A1 | COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS | STATE OF OREGON BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101085-A1 | Compounds And Methods For Modulating Activity Of Calcium Release Channels | RYR2, RYR1, CACNA1E | ALOX5 1635/4885OPRM1 965/4885OPRD1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.